Article thumbnail

Cell-Specific Dual Role of Caveolin-1 in Pulmonary Hypertension

By Rajamma Mathew

Abstract

A wide variety of cardiopulmonary and systemic diseases are known to lead to pulmonary hypertension (PH). A number of signaling pathways have been implicated in PH; however, the precise mechanism/s leading to PH is not yet clearly understood. Caveolin-1, a membrane scaffolding protein found in a number of cells including endothelial and smooth muscle cells, has been implicated in PH. Loss of endothelial caveolin-1 is reported in clinical and experimental forms of PH. Caveolin-1, also known as a tumor-suppressor factor, interacts with a number of transducing molecules that reside in or are recruited to caveolae, and it inhibits cell proliferative pathways. Not surprisingly, the rescue of endothelial caveolin-1 has been found not only to inhibit the activation of proliferative pathways but also to attenuate PH. Recently, it has emerged that during the progression of PH, enhanced expression of caveolin-1 occurs in smooth muscle cells, where it facilitates cell proliferation, thus contributing to worsening of the disease. This paper summarizes the cell-specific dual role of caveolin-1 in PH

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3109422
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A .D .v a nd e rM e e r ,M .M .K a m p h u i s ,A .A .P o o t ,J .F e i j e n
  2. (2007). A .J .P e a c o c k ,N .F .M u r p h y
  3. (2005). A role of STAT3 in Rho GTPase-regulated cell migration and proliferation,”
  4. (1995). a t h e w ,G .A .Z e b a l l o s ,H .T u n ,a n dM .H .G e w i t z ,“ R o l e of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats,”
  5. (1999). Abman et al., “Variable expression of endothelial no synthase in three forms of rat pulmonary hypertension,”
  6. (2007). Activation of signal transducerandtranscriptionof(STAT)3inhypoxia-induced pulmonary hypertension,”
  7. (2009). Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension. Potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease,”
  8. (2002). B.Razani,S.E.Woodman,andM.P.Lisanti,“Caveolae:from cell biology to animal physiology,”
  9. (1993). Calcium pump of the plasma membrane is localized in caveolae,” J o u r n a lo fC e l lB i o l o g y ,
  10. (2010). CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway,”
  11. (2008). Caveats of caveolin-1 in cancer progression,”
  12. (1999). Caveolin is an inhibitor of platelet-derived growth factor receptor signaling,”
  13. (2008). Caveolin regulates Kv1.5 trafficking to cholesterolrich membrane microdomains,”
  14. (2003). Caveolin-1 and caveolae act as regulators of mitogenic signaling in vascular smooth muscle cells,”
  15. (2011). Caveolin-1 assembles type 1 inositol 1,4,5-trisphosphate receptors and canonical transient receptor potential 3 channels into a functionalsignalingcomplexinarterialsmoothmusclecells,”
  16. (2010). Caveolin-1 deficiency dampens toll-like receptor 4 signaling through eNOS activation,”
  17. Caveolin-1 expression enhances endothelial capillary tubule formation,”
  18. (2004). Caveolin-1 expression is critical for vascular endothelial growth factorinducedischemichindlimbcollateralizationandnitricoxidemediated angiogenesis,”
  19. (2001). Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism,”
  20. (2001). Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation,”
  21. (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis,”
  22. Caveolin-1 is required for contractile phenotype expression by airway smooth muscle cells,”
  23. (2001). Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities,”
  24. (2008). Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells,”
  25. (2001). Caveolin-1 regulates transforming growth factor (TGF)-β/SMAD signaling through an interaction with the TGF-β type I receptor,”
  26. (2006). Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction,”
  27. (2008). Caveolin-1: an ambiguous partner in cell signalling and cancer,”
  28. (2006). Caveolin-1: dual role for proliferation of vascular smooth muscle cells,”
  29. (2003). Caveolin, caveolae, and endothelial cell function,”
  30. (2003). Caveolin1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway,”
  31. (2004). Caveolin1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav1 in cell invasiveness and matrix metalloproteinase (MMP2/9) secretion,”
  32. (2011). Caveolin1: a critical regulator of lung injury,”
  33. (2004). Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease,”BiochemistryandCellBiology,vol.82,no.1,pp.129– 144,
  34. (1999). Caveolins, liquid-ordered domains, and signal transduction,”
  35. (2011). Cells respond to mechanical stress by rapid disassembly of caveolae,”
  36. (2003). Cellular apoptosis is associated with increased caveolin-1 expression in macrophages,”
  37. (2007). Comhair et al., “Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension,”
  38. (1987). Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells,”
  39. (2002). Decreased endothelialnitric-oxidesynthase(eNOS)activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension,”
  40. (2002). Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice,”
  41. (2006). Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels,”
  42. (2004). Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension,”
  43. (2005). Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin1 in rat aorta,”
  44. (2001). E.Spisni,C.Griffoni,S.Santietal.,“Colocalizationprostacyclin (PGI2) synthase-caveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis,”
  45. (2002). Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs,”
  46. (2010). Emerging therapies for the treatment of pulmonary hypertension,”
  47. (2002). Engelman et al., “Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae,”
  48. (1998). Engelman et al., “Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade,”
  49. (2009). Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension,”
  50. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension,”
  51. (1953). Fine structure of blood capillaries,”
  52. (2003). Function of caveolae
  53. (1978). G.GabellaandD.Blundell,“Effectofstretchandcontraction on caveolae of smooth muscle cells,”
  54. (2005). Gene therapytargetingsurvivinselectivelyinducespulmonaryvascular apoptosis and reverses pulmonary arterial hypertension,”
  55. (2007). Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells,”
  56. (1998). High expression of endothelial nitric oxide synthase in plexiform lesionsofpulmonaryhypertension,”JournalofPathology,vol.
  57. (2006). High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension,”
  58. (2006). human airway smooth muscle,”
  59. (2006). Hypoxia and hypoxia-inducible factor-1α promote growth factor-induced proliferation of human vascular smooth muscle cells,”
  60. (2011). Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension,”
  61. (2007). Impaired apoptosisofpulmonaryendothelialcellsisassociatedwithintimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease,”
  62. (1990). Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger’s syndrome,”
  63. (2007). Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension,”
  64. (2010). Inflammation and pulmonary hypertension,”
  65. (1991). Inhibition of elastolysis by SC37698 reduces development and progression of monocrotaline pulmonary hypertension,”
  66. (2000). Inhibition of NOS enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats,”
  67. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells,” TheFASEBJournal,vol.19,no.9,pp.1178–1180,2005.
  68. (2005). K a w u t ,E .M .H o r n ,K .K .B e r e k a s h v i l i ,A .C .W i d l i t z
  69. (2000). Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo,”
  70. (2003). Lipid rafts: bringing order to chaos,”
  71. (1998). Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains,”
  72. (2009). Longterm effects of prenatal hypoxia on endothelium-dependent relaxation responses in pulmonary arteries of adult sheep,”
  73. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects
  74. (2006). Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension,”
  75. (1991). Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia,”
  76. (2004). Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression,”
  77. MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity,”
  78. (2006). Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degradingmatrixandnon-matrixsubstrates,”Cardiovascular Research,
  79. (1994). Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation,”
  80. (2002). Multiple functions of caveolin-1,”
  81. (2006). Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension,”
  82. (2008). Neutrophil caveolin-1 expression contributes to mechanism of lung inflammation and injury,”
  83. (2010). Nitric oxide synthase 3 and endothelin 1 immunoreactivity in pulmonary hypertension,”
  84. (2011). Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling,”
  85. (2001). Pag´ e, D.Gingras,andR.B´ eliveau,“Localizationofmembrane-type 1 matrix metalloproteinase in caveolae membrane domains,”
  86. (2009). Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration,”JournalofClinicalInvestigation,vol.119,no.7,pp.
  87. (2006). Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography,” Intensive CareMedicine,vol.32, no.6, pp.852– 857,
  88. (1987). Primary pulmonary hypertension. A national prospective study,”
  89. (2010). Progressiveendothelialcelldamageinaninflammatorymodelof pulmonary hypertension,”
  90. (2008). PTRFcavin, a conserved cytoplasmic protein required for caveola formation and function,”
  91. (2006). Pulmonary arterial hypertension in France: results from a national registry,”
  92. (2007). Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective,”
  93. (2003). Pulmonary hypertension in chronic obstructive pulmonary disease,”Pulmonary
  94. (2008). Pyrrolidine dithiocarbamaterestoresendothelialcellmembraneintegrity and attenuates monocrotaline-induced pulmonary artery hypertension,”
  95. (1995). Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,”
  96. (2007). Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice,”
  97. (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol,”
  98. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition,”
  99. (2007). RhoA activation and interaction with caveolin-1 are critical for pressureinduced myogenic tone in rat mesenteric resistance arteries,”
  100. (2008). Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation-Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells,”
  101. (2008). Role of caveolin-1 in regulation of inflammation: different strokes for different folks,”
  102. (1997). Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension,”
  103. (2000). Rudic et al., “In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation,”
  104. (2010). S.Saharan,R.Lodha,andS.K.Kabra,“Managementofacute lung injury/ARDS,”
  105. (2006). Short-term administration of a cellpermeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy,”
  106. (2005). Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension,”
  107. (2001). Smooth muscle excitation-contraction coupling:aroleforcaveolaeandcaveolins?”NewsinPhysiological Sciences,
  108. (2010). Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is inducedinmonocrotalineandhypoxiamodelsofpulmonary arterial hypertension,”
  109. (2006). SOCS proteins and caveolin-1 as negative regulators of endocrine signaling,”
  110. (2000). Sporadiac primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family,”
  111. (2005). STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells,”
  112. (2005). Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension,”
  113. (2006). T o r r e s ,J .C .T a p i a ,D .A .R o d r ´ ıguez et al., “Caveolin1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin,”
  114. (2001). T r e m b a t h ,J .R .T h o m s o n ,R .D .M a c h a d oe ta l . , “Clinical and molecular genetic features of pulmonary hypertensioninpatientswithhereditaryhemorrhagictelangiectasia,” The New England
  115. (1999). T u d e r ,C .D .C o o l ,M .W .G e r a c ie ta l . ,“ P r o s t a c y c l i n synthase expression is decreased in lungs from patients with severe pulmonary hypertension,”
  116. (2005). Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways,”
  117. (2011). Terguride ameliorates monocrotaline induced pulmonary hypertension in rats,”
  118. (2011). The acute respiratory distress syndrome: pathogenesis and treatment,”
  119. (2004). The caveolin proteins,”
  120. (1998). The endothelial nitric-oxide synthase-caveolin regulatory cycle,”
  121. (1955). The fine structure of the gall bladder epithelium of the mouse,”
  122. (2008). Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension,”
  123. (2004). Translocation of caveolin regulates stretchinduced ERK activity in vascular smooth muscle cells,”
  124. (2009). Updated clinical classification of pulmonary hypertension,”
  125. (2001). von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury,”
  126. (2004). Wong et al., “BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease,”